1Department of Urology, Chinese PLA General Hospital/PLA Military Postgraduate Medical School,Beijing 100853,China; 2Department of Urology,307 Hospital of PLA
Abstract：Metastatic renal cell carcinoma can't be cured by the existing various systemic treatment. Surgery is the only means to cure kidney cancer. Nephrectomy in still plays an important role in the treatment of metastatic kidney cancer, the emergence of targeted drugs provides a new choice for kidney cancer treatments. Current issue of preoperative neoadjuvant applications of targeted therapy includes treatment indications, drug safety and therapeutic effects of expectations, and the best treatment duration. This review focuses on the following two questions: ①The preoperation adminiatration of neoadjuvant targeted therapy for advanced kidney cancer patients have a reasonable theoretical basis? What type of clinical data (case report, Ⅱ/Ⅲ clinical trials) support this indications? ②What's the indications and the safety evaluation of new adjuvant target therapy?
[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007,57(1):43-66. [2]Sciarra A, Gentile V, Salciccia S, et al. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials, 2008,3(2):97-103. [3]Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995,13(3):688-696. [4]Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase Ⅱ trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol, 2010,28(13):2131-2136. [5]Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009,27(22):3584-3590. [6]Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial. Lancet, 2008,372(9637):449-456. [7]Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist, 2011,16 Suppl 2:45-50. [8]Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol, 2010,21(5):1027-1031. [9]Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007,356(2):125-134. [10]Escudier B, Albiges L, Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs, 2013,;73(5):427-438. [11]Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol, 2010,58(3):398-406. [12]Kapoor A, Gharajeh A, Sheikh A, et al. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol, 2009,16 Suppl 1:S60-66. [13]Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res, 2008,14(17):5579-5584. [14]Amin C, Wallen E, Pruthi RS, et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology, 2008,72(4):864-868.
